Kornimate/medical-research-clean huggingface dataset:
automated method for breast cancer detection

Conditions: Breast Cancer Diagnosis

Summary: participants with suspicious breast lesions by mammography will undergo fine needle aspiration (fna) under ultrasound guidance. the fna will be read by the cytopathologist and analyzed in the breast cancer detection cartridge. all patients will receive standard of care (ultrasound-guided core needle biopsy and diagnosis). we will also receive fna collected from 60 patients with palpable lesions in south africa and analyze them samples in our lab with the same method.


Eligibility criteria:
inclusion criteria: * patient must be female * patient must be 18 years of age or older * patient has been recommended for ultrasound core needle biopsy of a suspicious breast lesion exclusion criteria: * patients may be excluded for any condition that in the opinion of the investigator may not make it safe to take part (e.g. certain medicines).

Keywords: breast cancer diagnosis ultrasound-guided core needle biopsy fine needle aspiration fna diagnostic cartridge
radiotherapy to the prostate and dominant intra-prostatic lesion (dil)

Conditions: Prostate Cancer

Summary: the purpose of the study is to find out the feasibility and effects of ultra-hypofractionated radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate risk prostrate cancer.


Eligibility criteria:
inclusion criteria: * intermediate risk prostate cancer patients will be eligible for this study. risk groups will be assigned as per nccn guidelines. intermediate risk patients will be defined as: * psa 10-20 ng/ml or * gleason score = 7 or * clinical stage t2b/t2c * additionally, patients will be required to meet the following criteria: * age \>18 * kps \> 80 * prostate size \< 60cc * presence of a prostatic lesion with maximum dimension of \>/= 0.5cm and no more than two additional disease foci, each with a maximum dimension less than that of the dominant lesion. * international prostrate symptom score \< 15 * subjects must fill out the standard mri screening form and satisfy all mri screening criteria exclusion criteria: * prior androgen deprivation therapy for prostate cancer * evidence of metastatic disease on bone scan or mri/ct * mri ineligibility due to the presence of a cardiac pacemaker, defibrillator or other implanted metallic or electronic device which is considered mr unsafe, severe claustrophobia or inability to lie flat for the duration of the study, etc. * metallic hip implant, metallic implant or device in the pelvis that might distort the local magnetic field and compromise quality of mp-mri. * lateral pelvic separation greater than 50 cm and/or anterior-posterior separation greater than 35 cm which are incompatible with mrcat reconstruction * contra-indications to receiving gadolinium contrast * kps \< 80 * pelvic mri or ct (mri preferred) evidence of radiographic t3, t4 or n1 disease. * prior history of transurethral resection of the prostate * prior history of chronic prostatitis * prior history of urethral stricture * prior history of pelvic irradiation * history of inflammatory bowel disease * unable to give informed consent * unable to complete quality of life questionnaires * abnormal complete blood count. any of the following * platelet count less than 75,000/ml * hb level less than 10 gm/dl * wbc less than 3.5/ml * abnormal renal function tests (creatinine \> 1.5)

Keywords: 17-407 intermediate risk prostate cancer dil dominant intra-prostatic lesion
a study comparing a new dosing regimen of clot-dissolving drug for mechanical heart valves which show clots

Conditions: Prosthetic Valve Thrombosis

Summary: the optimal dosage and duration of administration of clot-dissolving medications for the treatment of patients with mechanical heart valves with clots is not known. we hypothesized that a large dose of the clot-dissolving medicine given initially (akin to the dose given in the treatment of heart attacks), might speed up the dissolution of the clot and rapidly restore the functioning of the mechanical heart valve.

the optimal fibrinolytic strategy for left sided prosthetic valve thrombosis (pvt) is not known. a large initial bolus dose of streptokinase (sk) might accelerate fibrinolysis and restore valve function more rapidly. this is a prospective, randomized trial comparing 2 fibrinolytic protocols in a first episode of pvt. in the rapid fibrinolytic protocol (rfp) 1.5 mu of sk is given over 1 hour, followed if required by a 0.1 mu/h infusion. in the standard protocol (sp) 0.25 mu is given over 30 minutes, followed by an infusion of 0.1 mu/h. serial echocardiography and fluoroscopy will be done to monitor therapy. the primary end point is the occurrence of a complete clinical response (ccr, complete hemodynamic response without any major complication). 58 patients are required in each arm for detecting a 30% difference with 80% power at α=0.05.

Eligibility criteria:
inclusion criteria: * first episode of left sided prosthetic valve thrombosis exclusion criteria: * contraindication to thrombolysis * refusal to give informed consent * pregnant women * age less than 12 years or more than 70 years * previous treatment for prosthetic valve thrombosis

Keywords: prosthetic valve thrombosis fibrinolysis streptokinase
efficacy and safety of a preparation containing an antibiotic and anti-inflammatory agent in acne vulgaris

Conditions: Acne Vulgaris

Summary: the concept behind our study was to combine an effect of antibiotic and anti-inflammatory agents for a more efficient acne therapy directed at the factors involved in the pathophysiology of the disease. for this purpose we evaluated a combination of clindamycin phosphate and salicylic acid in a non-irritating carrier.


Eligibility criteria:
inclusion criteria: * mild to moderate acne vulgaris; * at least 5 lesions on the face; * a one-month wash-out period was established for any topical or systemic drug use for treatment of acne vulgaris. exclusion criteria: * acne that was primarily truncal, nodular, or due to secondary causes/internal disease; * pregnancy, breastfeeding, or intention to become pregnant; * another dermatological disease of the face; * significant systemic disease; * any drug/alcohol addiction; * interacting medication; * known hypersensitivity to study medications; * history of chronic disease treated with medications which might affect acne condition and treatment outcome (e.g. corticosteroids, lithium, isoniazid, anti-androgens, phenytoin, phenobarbital) in the preceding month
health-related quality of life and functional impairments after intensive care unit discharge

Conditions: Health-related Quality of Life

Summary: diagnostic and therapeutic progress of the last twenty years has been accompanied by an evolution in the morbidity and mortality of intensive care unit (icu) patients. while there has been an overall decrease in mortality in the icu, nearly 20% of patients die within one year after icu discharge and survivors are marked by an increase in morbidity. indeed, independently of the initial disease, it is currently recognized that an admission to the icu can be experienced as a traumatic situation, with potential physical, psychological and cognitive impairments that can be described by the term "post-intensive care syndrome" (pics). this results in a decrease in quality of life compared to the general population. health-related quality of life (hrqol)has received increasing attention in the literature. thus, many studies have been interested in its evaluation, in particular in certain pathologies such as acute respiratory distress syndrome (ards), sepsis, cardiac arrest or in patients with onco-hematological diseases. paradoxically, few studies have described the hrqol and the elements of the pics in the overall population of patients admitted to the icu. however, a better understanding of these elements could allow us to propose improvement strategies to facilitate the rehabilitation of these patients.

the investigators therefore propose the constitution of a longitudinal cohort evaluating the hrqol, and allowing the analysis of its determinants in the global population of intensive care patients.

Eligibility criteria:
inclusion criteria: * all adult patients(age\>18) hospitalized in icu exclusion criteria: * legal guardianship * opposition to participate * unread and unwritten french language

Keywords: health-related quality of life morbidity long terms outcomes post intensive care syndrome intensive care unit
blaze-limiting approach in nmosd

Conditions: Neuromyelitis Optica Spectrum Disorders (NMOSD)

Summary: this is an observational cohort study based on data from the hospital-based nmosd registry (chinese medical research registration number mr-31-22-008563; chictr2000030651). between october 2023 (when eculizumab was approved for nmosd in china) and february 2025, 26 consecutive patients with aqp4-igg-positive nmosd received eculizumab, and 9 of them were included in this study.


Eligibility criteria:
inclusion criteria: (1)patients have been diagnosed with nmosd and tested seropositive for aqp4 antibody; (2) age ≥ 18 years; (3) received eculizumab during an acute phase of nmosd, defined as within 30 days of attack onset； (4) adherence to an 8-week follow-up from eculizumab initiation. exclusion criteria: 1. patients with unresolved neisseria meningitidis infection or severe infections that preclude the use of immunotherapy; 2. patients with severe comorbidities (such as heart failure, respiratory failure, severe hepatic or renal dysfunction, etc.); 3. patients with incomplete records of clinical symptoms and signs, as well as insufficient data on serum marker tests in their medical records.

Keywords: nmosd eculizumab aqp4-ab neuromyelitis optica spectrum disorders
efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of burkina faso

Conditions: Malaria

Summary: design: single-centre indication: malaria caused by plasmodium falciparum objectives: to determine and compare the efficacy of aq treatment in young children with uncomplicated falciparum malaria in the rural and the urban study area of the centre de recherche en santé de nouna (crsn). population: children aged 6-59 months with uncomplicated falciparum malaria (axillary temperature ≥ 37.5°c + ≥ 2.000 p. falciparum asexual parasites per µl blood) from the health centre situated in the villages of bagala, bourasso and kemena and from nouna town hospital outpatient department. sample size: n=120 treatment: all children will receive a total dose of 25 mg/kg oral aq over a period of three days (first and second day: 10mg/kg, third day: 5mg/kg). statistical procedures: the primary analysis parameter is the proportion of clinical failures on day 14. secondary parameters are the rate of clinical failures on day 28 (with and without pcr correction), the rate of early clinical failures, the rate of late parasitological failures (day 14 and day 28), and the rate of adverse events. data will be analysed in the overall group of study children and for rural (n=50) and urban (n=50) study children separately. study duration and dates: the study will be implemented in september-december 2005.


Eligibility criteria:
inclusion criteria: * age 6-59 months * uncomplicated falciparum malaria (axillary temperature ≥ 37.5°c and ≥ 2.000 p. falciparum asexual parasites per µl blood) * written informed consent given by the parents/caretakers exclusion criteria: * complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin \< 7 g/dl or haematocrit \< 21%) * any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition) * malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine.

Keywords: amodiaquine efficacy malaria burkina faso
quality of life of caregivers and patients suffering from multiple system atrophy

Conditions: Multiple System Atrophy

Summary: multiple system atrophy (msa) is a rare and fatal neurodegenerative disorder that cause as other neurodegenerative diseases profound declines in functioning and thus, require caregiving for assistance with daily living. the aim of the study is to evaluate the effect of a multimodal intervention as proposed by the nyu caregiver counseling and support intervention (nyuci) on the quality of life of patients and their caregivers.

multiple system atrophy (msa) is a rare and fatal neurodegenerative disorder, which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. no effective treatment is available. msa patients have a poor prognosis with a median survival ranging between 6 and 10 years. msa as other neurodegenerative diseases cause profound declines in functioning ; thus, many patients require caregivers for assistance with daily living. caregiving can also be extremely stressful, and many caregivers experience declines in mental health. all of these repercussions contribute to the deterioration of the caregiver's quality of life and they can have an impact on the patient, in particular, on the patient's survival. improving quality of life is a major element and identifying effective targeted interventions would bring immediate and direct benefit to patients and their families. in this context, it seems that a multimodal intervention as proposed by the nyu caregiver counseling and support intervention (nyuci) developed by mittelman could contribute to improve disease management and better coping with daily living difficulties. the nyuci strategy combines sessions of individual and family counseling, support group participation, and additional on-call telephone consultations in a flexible counseling approach that is tailored to each caregiving family

Eligibility criteria:
patients inclusion criteria : * patients suffering from "possible" or "probable" msa according to clinical consensus criteria * living at home * presence of at least one close person (family caregiver or not) in the entourage * unified multiple system atrophy rating scale (umsars) iv ≤4 * written informed consent * patient covered by the national health system caregivers inclusion criteria : * age \> 18 * able to answer to study scales and survey * written informed consent patients exclusion criteria: * unified multiple system atrophy rating scale (umsars) iv \> 4 * absence of at least one close person caregivers inclusion criteria : - enable to answer to study scales and survey

Keywords: multiple system atrophy quality of life multimodal intervention neurodegenerative disease
the 3q25 rs2305619 polymorphism associates with microvascular obstruction in stemi

Conditions: STEMI; Microvascular Coronary Artery Disease

Summary: the investigators enrolled 217 patients with acute stemi undergoing primary pci. the rs2305619 polymorphism was evaluated by real time pcr and plasma ptx3 concentration was assessed by human ptx3 elisa kit.

the investigators enrolled 217 patients with acute stemi undergoing primary pci in a tertiary care academic cardiovascular center. the rs2305619 polymorphism was evaluated by real time pcr and plasma ptx3 concentration was assessed by human ptx3 elisa kit. the primary outcome of the study was the incidence of coronary microvascular obstruction defined as thrombolysis in myocardial infarction (timi) grade \<3 flow after primary pci or timi grade 3 flow with myocardial blush grade 0 or 1. patients were grouped based on the genotypic variants (aa, ag and gg). the primary outcome was compared among the three variants, as well as the ptx3 concentration and 30-day mortality.

Eligibility criteria:
inclusion criteria: * patients with acute stemi with symptom onset \<12 h and treated by primary pci exclusion criteria: * stemi patients who received fibrinolytic therapy
comparison between d&c and hysteroscopy in management of aub in perimenopausal women

Conditions: Uterine Bleeding

Summary: the aim of this study is to compare dilatation and curettage with hysteroscopy in obtaining an accurate diagnosis of the etiology of abnormal uterine bleeding and outlining a mode of treatment-specific to the cause.

perimenopausal women complaining of abnormal uterine bleeding will be selected for assessment through detailed history taking, general and abdominal examination, local gynecological examination, transvaginal sonography (tvs) scanning and routine blood investigations. eligible participants in our study will be those who complain of menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia without local gynecological cause with failure of medical treatment for at least 3 months. all women participating in the study will be randomly allocated into two groups; dilatation and curettage (d\&c) group and hysteroscopy group. for women in the d\&c group, cervical dilatation and fractional endometrial curettage will be done under total intravenous (iv) anesthesia in operation theater and the curetting will be sent for histopathological examination. for women in the hysteroscopy group, hysteroscopy will be done under total iv anesthesia in operation theater hysteroscopic-guided curettings will also be taken and sent for histopathological examination.

Eligibility criteria:
inclusion criteria: * perimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause. * failure of medical treatment for at least 3 months. exclusion criteria: * age \ 55 years. * blood disorders or coagulopathy. * diagnosed or suspected local gynecologic lesion (polyp, adenomyosis, myoma, malignancy or cervical pathology). * use intrauterine contraceptive device. * pregnancy related conditions.

Keywords: abnormal uterine bleeding dilatation and curettage hysteroscopy
spironolactone and insulin resistance in chronic heart failure (chf)

Conditions: Chronic Stable Heart Failure

Summary: the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

diuretics is useful in chf patients. on the other hand, they deteriorate glucose metabolism. therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Eligibility criteria:
inclusion criteria: * chronic stable heart failure exclusion criteria: * renal dysfunction or under treatment with antidiabetic agents

Keywords: heart failure insulin resistance inflammatory cytokine spironolactone furosemide
a multicentre randomised controlled trial comparing two strategies for the diagnosis of invasive aspergillosis in high-risk haematology patients

Conditions: Invasive Aspergillosis

Summary: aspergillus is a fungus found in soil, on farms and on construction sites. in those whose immune system is impaired it causes severe infection. the people who are particularly at high-risk of infection with aspergillus (which is called invasive aspergillosis)are those with acute leukaemia who are having chemotherapy and those post bone marrow transplantation. currently 15% of those at high-risk develop invasive aspergillosis and 60-90% of those with invasive aspergillosis die. the main reason for this high death rate is that our current diagnostic tests are not good at detecting infection or often only detect the infection at advanced stages when treatment is ineffective. because of the limitations of current diagnostic tests the current practice is to give empiric antifungal therapy (eaft) early to treat suspected invasive aspergillosis. however studies have demonstrated that this therapy has only resulted in a minor reduction in the mortality rates and it also causes significant drug toxicity. it is a suboptimal treatment modality. new tests have recently been developed to diagnose invasive aspergillosis. these tests are for the detection of an aspergillus protein in blood and for the detection of aspergillus dna in blood. available data suggests that these new tests make an early diagnosis and seem to be able to monitor responses to treatment. however no study has been reported to date which demonstrates that the use of these tests can impact on important patient outcomes. this trial is being performed to determine whether the use of the new diagnostic tests to guide antifungal therapy will help improve treatment of invasive aspergillosis, reduce drug toxicity and reduce the death rate in the high-risk patients as compared with the current standard method of diagnosis and treatment with eaft.


Eligibility criteria:
inclusion criteria: patients fulfilling all the following criteria will be eligible for enrolment 1. aged 18-80 years 2. undergoing allogeneic haematopoietic stem cell transplantation (hsct) for any reason or undergoing intensive combination chemotherapy for acute myeloid leukaemia (aml) or acute lymphoblastic leukaemia (all) 3. has given written informed consent. - exclusion criteria: patients with any of the following will be ineligible for enrolment 1. other immunocompromised states (e.g. hiv infection, solid organ transplantation, autoimmune conditions treated with immunosuppressants etc.) besides those outlined in the inclusion criteria above 2. currently enrolled in an antifungal treatment trial (not an antifungal prophylaxis trial) 3. past history of proven or probable ia (as per standardized definitions) during a previous cycle of chemotherapy 4. currently have active ia or other active invasive fungal infection 5. prior enrolment in this study -
sodium-endothelial function-ckd study

Conditions: Kidney Failure, Chronic

Summary: heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. abnormalities of a metabolic pathway called the "l-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. the purpose of our research is to study the effects of sodium intake on the "l-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.

chronic kidney disease (ckd) is associated with abnormalities of endothelial function (ef) and nitric oxide (no) synthesis, and it is proposed that the endogenous no synthase inhibitor asymmetrical dimethylarginine (adma) plays a central role. in man adma is largely metabolized by dimethylarginine dimethylaminohydrolase (ddah), with some renal excretion occurring. sodium inhibits ddah expression in experimental animals and, given that ckd is frequently characterized by sodium retention, it would be interesting to study the effects of sodium loading on ddah activity/expression, adma levels and ef in ckd patients. to answer these questions, we have designed a double-blind cross-over study employing slow sodium (150 mmol/day) and placebo for seven days in individuals with mild-to-moderate ckd. changes in the ratio of urinary adma to dimethylamine (dma, an adma metabolite) will be used as an marker of ddah activity/expression. adma will be measured by elisa, dma by high performance liquid chromatography, and ef by venous occlusion plethysmography. we propose to test the following hypothesis; that in subjects with mild-to-moderate ckd under conditions of high sodium intake, as compared to low-normal sodium intake: (i) the ratio \[adma\]urine:\[dma\]urine is increased (ii) \[adma\]plasma is increased (iii) endothelium-dependent vasodilatation is reduced

Eligibility criteria:
inclusion criteria: * ckd stages 2 and 3 \[= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by cockcroft-gault formula\] * 18 to 75 years old exclusion criteria: * \>3 g/24 hours of proteinuria * uncontrolled hypertension (systolic bp \>160 mmhg, diastolic bp \>100 mmhg on/off anti-hypertensive medication) * diabetes mellitus * tobacco smoking * total fasting cholesterol \>6 mmol/l * uncontrolled heart failure or active ihd * chronic liver failure * active malignancy

Keywords: endothelial dysfunction adma ddah sodium